The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index; 18 of the 48 sources its claims cite were checked for support.
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Open accessAbstract
Clinical practice guidelines summarising diagnosis, risk stratification, and management of PBC including ursodeoxycholic acid, obeticholic acid, and off-label therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 of 48 cited sources checked · 7 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“Serum bilirubin has been recognised since the 1970s as a major predictor of poor outcome in PBC [72,7].”
What the sources say
- Supportedcites [72] 72. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-140. source
The 1979 paper’s Abstract (p. 137) identifies serum bilirubin as a predictor of prognosis in primary biliary cirrhosis. Its Presentation section reports that higher successive bilirubin levels were associated with shorter predicted survival, supporting the claim about poor outcome. (LLM, conf=0.93)
- Supportedcites [7] 7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349. source
The introduction (p. 2) calls serum bilirubin a well-established independent predictor of prognosis in PBC. Its cited references (p. 11) include a 1979 study titled “Serum bilirubin: a prognostic factor in primary biliary cirrhosis,” supporting the 1970s timeframe. (LLM, conf=0.91)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Male sex is associated with later diagnosis, more advanced disease at presentation, poorer biochemical response to UDCA therapy, and higher risk of developing hepatocellular carcinoma (HCC) [6,8,65].”
What the sources say
- Partly supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. sourceExperimental — accuracy not yet measured
The Results and Discussion (page not provided) report that men with PBC presented at an older age, had signs suggesting more advanced disease and delayed diagnosis, and were less likely to meet UDCA response criteria. The passages found do not address whether men have a higher risk of developing HCC, so this source does not support that part of the sentence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] 8. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016;65:321-329. source
- Not checked — no full text of the sourcecites [65] 65. Cheung A, Lammers WJ, Hirschfield GM, Invernizzi P, Mason A, Ponsioen CY, et al. Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis. J Hepatol 2015;62: S798-S799. source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients who present at a younger age (\45 years) are often symptomatic and less likely to respond well to standard treatment with UDCA [6].”
What the sources say
- Supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. source
The Results and Discussion (page not available in our copy) report that patients presenting at younger ages were more likely to have fatigue and pruritus and less likely to respond to UDCA. The paper specifically identifies age 45 as a response threshold for women; the age-related response effect was weaker in men. (LLM, conf=0.88)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The disease is chronic and often progressive, resulting in end-stage liver disease and its associated complications [6][7][8].”
What the sources say
- Partly supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. sourceExperimental — accuracy not yet measured
The Additional information section defines PBC-related failure to include liver transplantation or death from liver failure, supporting the possibility of severe outcomes. But the Discussion describes a potentially aggressive course particularly in younger patients, while characterizing the typical patient's course as relatively benign; it does not establish that PBC is often progressive to end-stage disease. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [7] 7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349. source
The introductory passage (p. 1) describes PBC as a chronic, slowly progressive disease that typically progresses to cirrhosis, which may lead to complications from liver failure. This supports the cited sentence’s description of progression to end-stage liver disease and associated complications. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [8] 8. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016;65:321-329. source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PBC recurrence has been reported in 20% of patients on average [253,258] but the rate of histological recurrence is likely higher [259].”
What the sources say
- Partly supportedcites [253] 253. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014;60:210-223. sourceExperimental — accuracy not yet measured
In the section on recurrence after liver transplantation (page unavailable), the paper reports recurrent PBC prevalence of 0–35% and 10-year incidence of 21–37%, but does not give a 20% average. It says recurrence can occur with normal liver tests and that biopsy practices affect reported rates, supporting the possibility of missed histological recurrence without quantifying how much higher its rate is. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [258] 258. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010;10:720-726. source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment with OCA is associated with a dose dependent exacerbation in pruritus, leading to treatment discontinuation in 4-10% of patients [130,131].”
What the sources say
- Partly supportedcites [130] 130. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148:751-761. sourceExperimental — accuracy not yet measured
The Discussion describes pruritus as clearly OCA dose-related, and Study Patients reports that pruritus was the principal reason for discontinuation (10%). The cited 4–10% range is not established by these passages: Adverse Events reports 13% discontinuation due to pruritus in the open-label extension. Page numbers were not available in our copy. (LLM, conf=0.88)
- Supportedcites [131] 131. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643. source
The Safety and Side Effects section reports more pruritus in the 5–10 mg and 10 mg groups than in the placebo group, with the highest incidence at 10 mg. It also reports that 8 of 217 patients (4%) withdrew because of pruritus overall, while 7 patients (10%) in the 10 mg group discontinued treatment for that reason. The 5–10 mg group's discontinuation rate was lower, at 1%. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PBC-specific ANA (antibodies against gp210 and sp100 antigens) are more frequently observed in patients with severe PBC and their presence may also be predictive of an unfavourable course, irrespective of serum bilirubin [75][76][77]63,78].”
What the sources say
- Not checked — no full text of the sourcecites [75] 75. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-437. source
- Partly supportedcites [76] 76. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibod- ies in primary biliary cirrhosis. Gut 2005;54:528-532. sourceExperimental — accuracy not yet measured
The Results and Discussion (page not available in our copy) associate PBC-specific ANA with more severe disease and worse outcomes, particularly for the multiple-nuclear-dot pattern. The study tested immunofluorescence patterns rather than separately establishing these findings for anti-gp210 and anti-sp100, and it does not show that the outcome association is independent of serum bilirubin. (LLM, conf=0.88)
- Partly supportedcites [77] 77. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-1144. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies gp210 and Sp100 as PBC-specific ANA targets and says PBC-specific ANA correlate with disease severity in cross-sectional studies. The Results (page unavailable) link anti-NPC antibodies, including anti-gp210, to poorer outcomes, but do not establish that anti-Sp100 predicts outcome. Anti-NPC added independent prognostic information only in patients with baseline bilirubin below 1 mg/dL, so the claim is too broad about prediction irrespective of bilirubin. (LLM, conf=0.88)
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment failure must be defined on validated surrogate endpoints to account for the slow progression of disease, i.e. endpoints that have significant reproducible prognostic performance in different cohorts of patients [100].”
What the sources say
- Partly supportedcites [100] 100. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52:349-359. sourceExperimental — accuracy not yet measured
The Endpoints of Clinical Trials in PBC section says slow progression makes death or transplantation impractical trial endpoints, and the Biochemical Markers section recommends biochemical markers as primary endpoints. But the paper does not say treatment failure must be defined by validated surrogates with reproducible prognostic performance across different cohorts; it allows several ways to assess response. Page numbers were not available in our copy. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“continuous scoring systems incorporating both measures of treatment response and parameters of disease severity [106,107].Thus, both the GLOBE score and the UK-PBC score have shown better performance for the prediction of death or liver transplantation than the Paris-I criteria, which have the best performance among binary models.”
What the sources say
- Partly supportedcites [106] 106. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149:1804-1812. sourceExperimental — accuracy not yet measured
The Performance of the GLOBE Score Compared With Other Criteria section says GLOBE discriminated outcomes better than the earlier criteria; Table 3 reports higher C-statistics for GLOBE than Paris-1 and the other binary criteria. The paper also describes Paris-1 as generally having the best predictability among those criteria. It does not evaluate the UK-PBC score, so it cannot support that score’s claimed superiority to Paris-1; its mention of the UK-PBC consortium is not a comparison of scores. (LLM, conf=0.88)
- Partly supportedcites [107] 107. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK- PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatol- ogy 2016;63:930-950. sourceExperimental — accuracy not yet measured
The Validation of the PBC Risk Score section reports higher AUCs for UK-PBC than for Paris I, and Paris I has the highest AUCs among the four binary models compared. The paper does not report a GLOBE-score comparison, so it does not support that part of the claim. (LLM, conf=0.88)
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The enhanced liver fibrosis (ELF) score, which is computed from the simultaneous measurements of serum concentrations of hyaluronic acid, procollagen III peptide and tissue inhibitor of metalloproteinase 1, have shown similar predictive capacity [74].”
What the sources say
- Supportedcites [74] 74. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008;48:1549-1557. source
The Methods identify hyaluronic acid, procollagen type III N-terminal propeptide, and TIMP-1 as components of the ELF assay. The Results report no statistically significant difference between ELF and histological staging in predicting clinical outcomes in patients with primary biliary cirrhosis, supporting similar predictive capacity in that comparison. (LLM, conf=0.90)
- Supported
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A diagnosis of primary biliary cholangitis is made if patients meet at least two of the following criteria: have biochemical evidence of chronic cholestasis, positive anti-mitochondrial antibodies in sera, and histological features compatible with primary biliary cholangitis.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the treatment response to ursodeoxycholic acid was incomplete in about 20-40% of patients with primary biliary cholangitis after 1 year, as judged by various biochemical criteria, either binary or continuously.3”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, primary biliary cholangitis is characterised by persistent elevation of cholestatic liver enzymes, including alkaline phosphatase and gammaglutamyl transpeptidase (GGT), and detection of antimitochondrial antibodies or primary biliary cholangitis-specific anti-nuclear antibodies (anti-sp100 or anti-gp210).[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Non-invasive liver stiffness measurement (LSM) has proven useful as an alternative to invasive liver biopsy for the evaluation of liver fibrosis, and LSM using transient elastography is recommended at the time of diagnosis.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical practice guidelines from the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases (AASLD), and the Asian-Pacific Association for the Study of the Liver recommend ursodeoxycholic acid treatment (13-15 mg/kg per day) for all patients with primary biliary cholangitis and elevated cholestatic enzymes.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Ursodeoxycholic acid is standard-of-care treatment for primary biliary cholangitis.”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“For treatment, clinical indices have been developed to establish ursodeoxycholic acid treatment response at 1-2 years by biochemical tests, either binary or continuously.3”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the liver stiffness measurement (LSM) in stratifying the risk for progression has been confirmed.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Ursodeoxycholic acid, a hydrophilic bile acid with choleretic and liver-protective properties, is currently the standard firstline therapy for primary biliary cholangitis.2,3”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [2]
In the citing paper
“For sertraline as fourth-line treatment, no sufficient data for sclerosing cholangitis-associated itch exist.20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“Rifampicin was so far regarded as the most effective evidence-based treatment of cholestasis-associated pruritus, but it may induce drug-induced hepatitis after 4-12 weeks in up to 12% of cholestatic patients while the first 2 weeks are regarded as safe.20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“The evidence for the antipruritic effectiveness of the non-absorbable anion exchange resin cholestyramine in sclerosing cholangitis is limited when compared to PBC, 20,51 and that of the more potent anion exchange resin colesevelam is non-existent.217”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“Abdominal discomfort | 20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| No evidence for PSC | Sertraline (50-75 mg/d) | | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| No evidence for PSC | Anion exchange resins (cholestyramine [4 g once to four | Abdominal discomfort | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| 2 nd line | Rifampicin (150-300 mg/d) | Hepatitis | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| 3 rd line | Naltrexone (12.5-50 mg/d) | Opioid withdrawal syndrome | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“In PBC, UDCA is used as first-line treatment,2 66 67 but 30%–50% of patients respond insufficiently (based on biochemical criteria)”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [66]
In the citing paper
“Current guideline-recommended medical treatment options for pruritus of cholestasis include the anion exchange resin cholestyramine, the pregnane X receptor (PXR) agonist rifampicin, the opioid antagonist naltrexone, and the selective serotonin reuptake inhibitor sertraline.4,7 Efficacy or tolerability of these drugs, or both, are limited.8,9”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [4]
In the citing paper
“Studies investigating the association between bone diseases and chronic liver disease have mainly focused on cholestatic liver diseases [20].”
From Bone diseases in patients with chronic liver disease (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Transplant-assessment bilirubin threshold has conflicting units
MinorThe recommendation pairs a bilirubin threshold of 50 mmol/L with 3 mg/dl, while the transplantation discussion pairs a threshold of 50-85 lmol/L with 3-5 mg/dl. The two passages give incompatible units for the same approximate threshold.
“persistent elevated bilirubin values [50 mmol/L or 3 mg/dl]”
“bilirubin values are rising progressively above 50-85 lmol/L (3-5 mg/dl)”
LDL is described as both elevated and not elevated
MinorThe hyperlipidaemia section reports elevated LDL in early disease and says it may rise further, but later states that LDL cholesterol is not elevated.
“In early disease, elevated very low density lipoprotein (VLDL) and LDL concentrations are reported, as well as significantly elevated HDL values.As disease progresses, LDL may increase further”
“It is clinically significant that HDL cholesterol is elevated whilst LDL cholesterol is not”
Citations
Cites
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citation(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Flagged first, then by citations
Research works printed but not linked: 1
- Corpechot, 2016, Relationships between biochemical response to UDCA and progression of liver stiffness as determined by Fibroscan in patients with PBC, Hepatology, 64, 194A
Cited by
Sorted by citations
Items 401–500 of 1,481
Yu, K., Li, P., Xu, T., Xu, J., Wang, K., Chai, J., Zhao, D., Liu, Y., Wang, Y., Ma, J., et al. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153291 · Cited by 17
Zhang, W., Liu, L., Zhang, M., Zhang, F., Peng, C., Zhang, B., Chen, J., Li, L., He, J., Xiao, J., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00124 · Cited by 7
Wang, L., Sun, K., Ai, T. I. A. N., Yansheng, L. I. U., Zhang, M., Zhou, X., & Han, Y. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07316-x · Cited by 17
Enzymes of Fibrosis in Chronic Liver Disease
Tsomidis, I., Notas, G., Xidakis, C., Voumvouraki, A., Samonakis, D. N., Koulentaki, M., & Kouroumalis, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123179 · Cited by 18
Levy, C., Buchanan-Peart, K.-A., MacEwan, J. P., Levine, A., Nair, R., Wheeler, D., Bessonova, L., Goel, A., Gish, R. G., & Bonder, A. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000677 · Cited by 16
Testosterone affects female CD4+ T cells in healthy individuals and autoimmune liver diseases
Henze, L., Will, N., Lee, D., Haas, V., Casar, C., Meyer, J., Stein, S., Mangler, F., Steinmann, S., Poch, T., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184544 · Cited by 18
Self-citationLytvyak, E., Hirschfield, G. M., Shreekumar, D., Wong, Y. J., & Montaño‐Loza, A. J. (2025) · Liver International · doi:10.1111/liv.70190 · Cited by 17
“Similarly, risk factors for advanced fibrosis in PBC have been identified as younger age at onset, male sex, and results from selected biochemical/serological indices (bilirubin, albumin) pre-and post-therapy with UDCA [71].”
Self-citationDing, D.-W., Xuan, G.-Y., Hu, Y.-N., Yu, J.-H., Liu, Y.-S., Guo, G.-Y., Ma, S.-Y., Yang, F.-F., Tian, S.-Y., Ma, G., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1907 · Cited by 16
Lei, W., Zhao, C., Sun, J., Jin, Y., & Duan, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112733 · Cited by 16
Xu, C., Yue, R., Lv, X., Wang, S., & Du, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835991 · Cited by 17
“The first-line treatment drugs were mainly bile acid-binding resin (Gideon et al., 2017), such as colesevelam hydrochloride, which has better therapeutic effect than cholestyramine.”
BackgroundClinical and biochemical understanding of Zinc interaction during liver diseases: A paradigm shift
Lubna, S., & Ahmad, R. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127130 · Cited by 15
Olianas, A., Guadalupi, G., Cabras, T., Contini, C., Serrao, S., Iavarone, F., Castagnola, M., Messana, I., Onali, S., Chessa, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020959 · Cited by 18
Rigopoulou, E. I., Bakarozi, M., Dimas, I., Galanis, K., Lygoura, V., Gatselis, N., Koulentaki, M., & Dalekos, G. N. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0098 · Cited by 16
Ding, D., Guo, G., Cui, L., Jia, G., Wang, X., Zhang, M., Tian, S., Zheng, L., Liu, Y., Hu, Y., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10587-w · Cited by 20
“Referring to the diagnostic criteria established in the 2017 Guidelines [14] for the diagnosis and treatment of PBC, PBC can be diagnosed by meeting any two of the following three criteria: (1) Elevated ALP, an indicator of cholestasis, and imaging that rules out extrahepatic or intrahepatic bile…”
BackgroundMethodZhao, D., Yan, H., Han, Y., Zhang, W.-M., Zhao, Y., & Liao, H.-Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1142177 · Cited by 16
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000826 · Cited by 17
“PBC treatment has evolved with the introduction of alternative UDCA options, emphasizing the importance of assessing the response to the first-line therapy [4] However, most studies generating efficacy and safety data for OCA and fibrates have focused on populations without cirrhosis.”
InfluentialWang, Q., Tang, X., Qiao, W., Sun, L., Shi, H., Chen, D., Xu, B., Liu, Y., Zhao, J., Huang, C., et al. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105368 · Cited by 18
Montaño‐Loza, A. J., Lytvyak, E., Hirschfield, G. M., Hansen, B. E., Ebadi, M., Berney, T., Toso, C., Magini, G. M., Villamil, A., Nevens, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.010 · Cited by 17
Self-citationLi, S. X., Lv, T., Zhang, C., Wang, T., Tian, D., Sun, G., Wang, Y., Zhao, X., Duan, W. J., Chen, S., et al. (2019) · Liver International · doi:10.1111/liv.14136 · Cited by 16
Couto, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Porta, G., Levy, C., Silva, A. E. B., Bittencourt, P. L., de Carvalho‐Filho, R. J., CHAVES, D. M., Miura, I. K., et al. (2019) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201900000-43 · Cited by 16
“…of PBC patients and the diagnosis should be established when two of those three criteria are met: ALP elevation, presence of AMA, liver biopsy with typical findings In addition, in the absence of AMA, other PBC-specific autoantibodies: such as sp100 or gp210 are useful for diagnosis (25,26) .”
BackgroundPrevalence of Celiac Disease in Patients with Primary Biliary Cholangitis
Callichurn, K., Cvetkovic, L., Therrien, A., Vincent, C., Hétu, P., & Bouin, M. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwz039 · Cited by 15
The use of biologics in the treatment of autoimmune liver disease
Chang, C. C.-C., Tanaka, A., Bowlus, C. L., & Gershwin, M. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1733527 · Cited by 16
Kempińska‐Podhorodecka, A., Adamowicz, M., Chmielarz, M., Janik, M. K., Milkiewicz, P., & Milkiewicz, M. (2020) · Nutrients · doi:10.3390/nu12082244 · Cited by 17
“All patients with PBC met The European Association for the Study of the Liver (EASL) criteria for the diagnosis of PBC [22].”
MethodKawata, K., Joshita, S., Shimoda, S., Yamashita, Y., Yamashita, M., Kitsugi, K., Takatori, S., Ohta, K., Ito, J., Shimoyama, S., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13584 · Cited by 16
Novel strategies and therapeutic options for the management of primary biliary cholangitis
Khanna, A., & Jones, D. E. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17728669 · Cited by 16
Self-citationLarge-duct cholangiopathies: aetiology, diagnosis and treatment
Menon, S., & Holt, A. P. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101098 · Cited by 16
Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?
Warnes, T. W., Roberts, S. A., Smith, A., Haboubi, N. Y., & McMahon, R. F. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205958 · Cited by 16
Primary biliary cholangitis and the narrowing gap towards optimal disease control
Cançado, G. G. L., Lleò, A., Levy, C., Trauner, M., & Hirschfield, G. M. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00025-1 · Cited by 20
Self-citationAutoantibodies in Primary Biliary Cholangitis
Leung, K. K., & Hirschfield, G. M. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.004 · Cited by 15
“Preferably, testing for AMA should be done using IFT on rodent kidney/liver tissue and confirmation of fluorescence pattern using human larynx epithelial cancer cell line (Hep-2) cells and solid-phase test systems such as enzyme-linked immunosorbent assays (ELISAs) using bovine or porcine heart mitochondrial fractions…”
BackgroundMethodSelf-citationAutoimmune liver disease and multiple sclerosis: state of the art and future perspectives
Villani, R., Serviddio, G., Avolio, C., Cassano, T., & D’Amico, E. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01128-8 · Cited by 16
Marrone, G., Covino, M., Merra, G., Piccioni, A., Amodeo, A., Novelli, A., Murri, R., Pompili, M., Gasbarrini, A., & Franceschi, F. (2023) · Liver International · doi:10.1111/liv.15736 · Cited by 15
“14,15 UDCA has been found to have non-hepatic effects in various pathophysiological models, such as cystic fibrosis lung disease and airway inflammation, showing significant improvement in all histopathological changes that oc-curred in the context of airway remodelling.”
BackgroundTian, S., Hu, Y., Zhang, M., Wang, K., Guo, G., Li, B., Shang, Y., & Han, Y. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03163-y · Cited by 15
Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease.
Huang, W., Cao, Z.-J., Wang, W.-X., Yang, Z.-C., Jiao, S.-X., Chen, Y., Chen, S.-L., Zhang, L.-Y., & Li, Z. (2024) · Bioorganic chemistry (Print) · doi:10.1016/j.bioorg.2023.107071 · Cited by 15
Association of chronic liver disease with bone diseases and muscle weakness
Saeki, C., Saito, M., & Tsubota, A. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01488-x · Cited by 18
“In particular, alendronate (weekly) and ibandronate (monthly) have been reported to effectively increase bone mass in patients with PBC [156].”
InfluentialGóméz, E., Montero, J. L., Molina, E., Garcı́a-Buey, L., Casado, M., Fuentes, J., Simón, M. Á., Díaz‐González, Á., Jorquera, F., Morillas, R. M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18004 · Cited by 15
Hashimoto, T., & Okuno, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17565 · Cited by 15
Risk stratification and prognostic modelling in primary biliary cholangitis
Goet, J. C., Harms, M. H., Carbone, M., & Hansen, B. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.006 · Cited by 16
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis
Manno, V., Gerussi, A., Carbone, M., Minelli, G., Taruscio, D., Conti, S., & Invernizzi, P. (2019) · Hepatology Communications · doi:10.1002/hep4.1407 · Cited by 14
Self-citationEpigenetics of Primary Biliary Cholangitis
Li, Y., Tang, R., & Ma, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3449-2_10 · Cited by 14
The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease
Jin, H. S., Hwang, J., Lee, L. E., Park, Y., & Song, J. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244950 · Cited by 15
Type I interferon detection in autoimmune diseases: challenges and clinical applications
Papadopoulos, V. E., Skarlis, C., Evangelopoulos, M., & Mavragani, C. P. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1939686 · Cited by 15
Gentilucci, U. V., Rosina, F., Pace-Palitti, V., Sacco, R., Pellicelli, A. M., Chessa, L., Vincentis, A. D., Barlattani, M., Barlattani, A., Feletti, V., et al. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1669702 · Cited by 14
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review
Mago, S., & Wu, G. Y. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00036 · Cited by 18
Graf, M., Lange, C. M., Langer, M., Schattenberg, J. M., Seeßle, J., Dietz, J., Vermehren, A., Michael, F. A., Mondorf, A. W., Zeuzem, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227047 · Cited by 19
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 15
Myeloid cells in chronic liver inflammation
Patseas, D., El-Masry, A., Liu, Z., Ramachandran, P., & Triantafyllou, E. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01324-4 · Cited by 20
Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?
Christen, U., & Hintermann, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898615 · Cited by 18
Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis
Medina‐Morales, E., Barba, R., Gerger, H., Goyes, D., Trivedi, H. D., Ferrigno, B. W., Patwardhan, V. R., & Bonder, A. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001797 · Cited by 16
Wang, R., Lin, Q., Lu, Z., Wen, H., Hu, F., You, J., He, Y., Fang, Y., Bian, Z., Hou, Q., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103163 · Cited by 14
Reasons why women are more likely to develop primary biliary cholangitis
Ma, D., Ma, J., Zhao, C., & Tai, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25634 · Cited by 18
Qian, Q., Wu, Y., Cui, N., Li, Y., Zhou, Y., Li, Y., Lian, M., Xiao, X., Miao, Q., You, Z., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103289 · Cited by 15
Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Sundaram, S., Kiran, S., Mazumdar, S., et al. (2018) · ACG Case Reports Journal · doi:10.14309/crj.2018.54 · Cited by 14
Maevskaya, M. V., Ivashkin, V. T., Владимирович, И. К., Lunkov, V. D., Liusina, E. O., Zozula, V. N., & Ивановна, Л. В. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.02.000122 · Cited by 14
Silva, M. J., Dellavance, A., Baldo, D. C., Rodrigues, S. H., Grecco, M., Prado, M. S., Agustinelli, R. D. A., & Andrade, L. E. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798322 · Cited by 16
Laursen, T. L., Bossen, L., Pihl, R., Troldborg, A., Sandahl, T. D., Hansen, A. G., Folseraas, T., Vesterhus, M. N., Grønbæk, H., & Thiel, S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00515 · Cited by 15
Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination
Lee, S. K., Kwon, J. H., Yoon, N., Lee, S. H., & Sung, P. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.029 · Cited by 14
Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis
Zhang, H., Li, S., Feng, Y.-H., Zhang, Q., & Xie, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00904-2 · Cited by 14
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 15
Bombaci, M., Pesce, E., Torri, A., Carpi, D., Crosti, M., Lanzafame, M., Cordiglieri, C., Sinisi, A. M., Moro, M., Bernuzzi, F., et al. (2019) · Liver International · doi:10.1111/liv.14128 · Cited by 14
Self-citationKuznietsova, H. M., Dziubenko, N., Lynchak, O. V., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05730-3 · Cited by 14
Arvaniti, P., Zachou, K., Lyberopoulou, A., Gatselis, N., Brooks, W. H., Dalekos, G. N., & Renaudineau, Y. (2019) · Epigenomes · doi:10.3390/epigenomes3030015 · Cited by 14
Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia
Eastern Slovakia PBC Group, Dražilová, S., Babinská, I., Gazda, J., Halánová, M., Janíčko, M., Kucinsky, B., Šafčák, D., Martinkova, D., Tarbajova, L., et al. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01391-6 · Cited by 14
Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners
Canivet, C. M., Smati, S., Lannes, A., Brisseau, J., Judon, L., Roch, M. L., Cariou, B., Bellanger, W., Guerci, B., & Boursier, J. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101848 · Cited by 14
Roth, D., Düll, M. M., Horst, L. J., Lindemann, A., Malzer, X., Koop, K., Zundler, S., Vetter, M., Jefremow, A., Atreya, R. N., et al. (2024) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjae131 · Cited by 14
Self-citationBarriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
Corrigan, M., Hirschfield, G. M., Greenfield, S., & Parry, J. M. (2019) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2018-000226 · Cited by 13
Self-citationNon-dermatological Challenges of Chronic Itch
Kremer, A. E., Mettang, T., & Weißhaar, E. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3345 · Cited by 13
Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
Pugliese, N., Arcari, I., Aghemo, A., Lania, A. G., Lleò, A., & Mazziotti, G. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i14.1430 · Cited by 14
Guoyun, X., Dawei, D., Ning, L., Yinan, H., Fangfang, Y., Siyuan, T., Hao, S., Jiaqi, Y., Ang, X., Guanya, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948362 · Cited by 13
“…of fenofibrate, and there is no relevant research report on the dosage of fenofibrate (Chinese Society of Hepatology and ChineseMedical Association, 2022; European Association for the Study of the Liver, 2017; Lindor et al., 2018), the meta-analysis is still needed to provide medical evidence.”
BackgroundSecondary bile acids and the biliary epithelia: The good and the bad
Lenci, I., Milana, M., Signorello, A., Grassi, G. B., & Baiocchi, L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.357 · Cited by 13
Mulcahy, V., Liaskou, E., Martín, J., Kotagiri, P., Badrock, J., Jones, R. L., Rushbrook, S., Ryder, S. D., Thorburn, D., Taylor-Robinson, S. D., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000110 · Cited by 14
Self-citationGatselis, N., Zachou, K., Montaño‐Loza, A. J., Cançado, E. L. R., Arinaga‐Hino, T., Muratori, P., Efe, C., Floreani, A., Invernizzi, P., Takahashi, A., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.06.001 · Cited by 13
Self-citationThe effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models
Wang, Z., Liu, Z., Zheng, J., Huang, L.-X., Jin, R., Wang, X., Chen, D., Xie, Y., & Feng, B. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03176-0 · Cited by 13
Understanding fatigue and pruritus in primary biliary cholangitis
Faisal, A. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000216 · Cited by 14
“[5] Regarding future treatment options, seledelpar, a selective peroxisome proliferator-activated receptor delta agonist, and S-adenosyl-L-methionine, when combined with ursodeoxycholic acid, have demonstrated improved sleep quality and reduced fatigue in open-label trials among patients with PBC.”
Li, H., Liu, S., Wang, X., Feng, X., Wang, S., Zhang, Y., Zhang, F., Wang, L., Xu, T., & Li, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0416 · Cited by 15
Ding, D., Jia, G., Cui, L., Liu, Y., Wang, X., Sun, R., Deng, J., Guo, G., Shang, Y., & Han, Y. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.12.024 · Cited by 13
Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 14
Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 14
Poyatos-Canton, E., Morandeira, F., Climent, J., Mas, V., Castellote, J., & Bas, J. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108749 · Cited by 14
Bauer, A., Habior, A., & Gaweł, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040801 · Cited by 15
Chen, S., Li, M., Duan, W., Li, B. E., Li, S., Lv, T.-T., Ma, L., & Jia, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.05.009 · Cited by 12
Huang, C., Zhang, H., Han, W., Zhao, D., Liao, H.-Y., Yin-xue, M., Xu, B., Li, L., Han, Y., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984697 · Cited by 13
From volume to value: a watershed moment for the clinical laboratory
Tomaiuolo, R., & Banfi, G. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0870 · Cited by 13
Rigamonti, C., Cittone, M. G., Manfredi, G. F., De Benedittis, C., Paggi, N., Baorda, F., Di Benedetto, D., Minisini, R., & Pirisi, M. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2023.100952 · Cited by 15
Knowledge regarding hepatitis B mother‐to‐child transmission among healthcare workers in South China
Chen, Y., Chen, Y., Xie, C., et al. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12839 · Cited by 13
Yan, X., & Jin, J. (2018) · Medicine · doi:10.1097/md.0000000000010004 · Cited by 13
Geoepidemiology and (epi-)genetics in primary biliary cholangitis
Roberto, R., Laura, C., Tanaka, A., & Invernizzi, P. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.05.011 · Cited by 14
Self-citationQian, J., Yao, T.-T., Wang, Y., & Wang, G. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.03.026 · Cited by 13
Chen, S., Lv, T., Sun, G., Li, S., Duan, W., Zhang, C., Jin, H., Tian, D., Li, M., Shan, S., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10267-7 · Cited by 13
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14
Cost of illness of Primary Biliary Cholangitis - a population-based study
Gerussi, A., Restelli, U., Croce, D., Bonfanti, M., Invernizzi, P., & Carbone, M. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.07.029 · Cited by 13
Self-citationNon-invasive diagnosis and follow-up of primary biliary cholangitis
Corpechot, C., Heurgué, A., Tanné, F., Potier, P., Hanslik, B., Decraecker, M., de Lédinghen, V., Ganne‐Carrié, N., Bureau, C., & Bourlière, M. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101770 · Cited by 15
Self-citationНиколаевич, Б. С., Morozov, S. V., Vinnitskaya, E. V., Сергеевна, С. Е., Борунова, Ж. В., Dorofeev, A., Sandler, Y. G., Германович, С. К., Kostyushev, D. S., Brezgin, S., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01983-5 · Cited by 12
Melatonin attenuates cholestatic liver injury via inhibition of the inflammatory response
Tan, Y., Zhao, N., Xie, Q., et al. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04682-7 · Cited by 12
“In addition, PBC patients ( n = 11) were diagnosed according to the European Association for the Study of the Liver criteria [10].”
MethodSpleen stiffness: a new tool to predict high‐risk varices in cirrhotic patients
Gaspar, R., Silva, M., Cardoso, P., Gonçalves, R., Andrade, P., & Macedo, G. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16344 · Cited by 13
CT and MR imaging of primary biliary cholangitis: a pictorial review
Zhang, Y., Zheng, T., Huang, Z., & Song, B. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01517-3 · Cited by 12
Targeting bile salt homeostasis in biliary diseases
Trampert, D. C., Kunst, R. F., & van de Graaf, S. F. J. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000997 · Cited by 11
Liang, Y., Li, J., Zhang, Z., Jiang, T., & Yang, Z. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102321 · Cited by 14
Are Gender Differences Important for Autoimmune Liver Diseases?
Floreani, A., Gabbia, D., & Martin, S. D. (2024) · Life · doi:10.3390/life14040500 · Cited by 14
“Factors responsible for gender differences in PBC include sexual hormones and genetic factors (Figure 2).”
BackgroundMa, Y., Zou, C., Yang, Y., Fang, M., Guan, Y., Sun, J., Gao, Y., Shang, Z., & Zhang, X. (2024) · Food & Function · doi:10.1039/d4fo02158d · Cited by 12
Wiegand, J., Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., Naumann, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2382-7720 · Cited by 12
“PBC guidelines emphasise the impact of pruritus, fatigue, and sicca syndrome on quality of life and recommend that 90% of PBC patients have at least a yearly standardised documentation of symptoms [1].”
Influential
Metadata
- Authors
- Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C.
- Affiliations
- European Association for the Study of the Liver (CH)
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 67
- Issue
- 1
- Pages
- 145-172
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2605729742
- Semantic Scholar
- a6a2b9566f65a4e01153b95ecdcd0d4106d9fed9
- Cited by
- 1,480
- References
- 274
- Citations by year
- 2026: 166 · 2025: 207 · 2024: 205 · 2023: 178 · 2022: 175 · 2021: 140 · 2020: 136 · 2019: 131 · 2018: 111 · 2017: 30
- FWCI
- 68.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- European Association for the Study of the Liver
- DFG
- Helmut and Hannelore Greve Foundation
- YAEL-Foundation
- NIHR
- Birmingham Liver Biomedical Research Centre
- EU Marie Curie scheme
- Newcastle Biomedical Research Centre
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune cholestatic liver disease, antimitochondrial antibodies, cholestatic hepatitis, risk stratification, ursodeoxycholic acid, obeticholic acid, fibrates, budesonide, off-label therapy, individualized care, diagnosis, management
- MeSH terms
- Cholangitis, Female, Humans, Male, Prognosis, Ursodeoxycholic Acid, Liver Transplantation, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-26 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
